Your end-to-end CDMO partner for your viral vector projects
Learn more about us
WHO ARE WE?
We are a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of gene therapies, oncolytic viruses and vaccine candidates. Our teams of experts based at our 3 sites – in Europe and US – are devoted to supporting innovative projects and help reduce overall timelines and costs.
Our mission is to provide GMP viral vectors from early-stage to market, contributing to the success of our clients’ immunotherapy and gene therapy innovations.
We offer a broad range of viral vectors, including AAV, LVV, MVA, Poxvirus, Vaccinia, Measles, and more.
Our CDMO services include manufacturing of bulk drug substance, fill-finish of drug products, process and assay development, bioanalytical testing and regulatory support.
We place the client at the heart of everything we do. We implement strategies to achieve best-in-class customer experience. A team of experts is dedicated to your project to provide you with the best innovative solutions adapted to your needs.
1994
first viral vector facility in Europe
3 facilities (France & USA)
~300 employees
>25 years of experience
in viral vectors (manufacturing)
Fill & Finish up to 10 000 vials/batch
OUR HISTORY
ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of oncolytic viruses, gene therapies, and vaccine candidates based on viral vectors.
We are grounded in the Mérieux family’s legacy of biology and vaccine expertise, dating back to 1897.
As a pioneer, we have been developing and producing viral vectors since the 1990s. We started with Pox Virus, MVA, Vaccinia and oncolytic viruses to support our clients’ clinical trials with the ultimate goal of fighting smallpox and several types of cancer.
We have continuously added new viruses to our portfolio, including manufacturing of AAVs in 2016 through adherent and suspension processes. Based on this strong expertise in virology and cell culture, in 2022 we decided to develop our high predictable yield and versatile AAV platform to manufacture different serotypes.
More than ever, our vision is to contribute to a long-term public health vision where Bio-Industry has a central role for a healthier world.
1961
1968
1985
2001
2004
2011
2014
2016
2018
1961
Bionetics Research Laboratory was established
1968
Acquired by Litton Industries.
Expanded activities in retrovirus and cancer research
1985
Organon Teknika acquires R&D and diagnostic assets, renames company ABL
2001
ABL acquired by bioMérieux.
ABL becomes an Institut Mérieux Company
2004
ABL spun out from bioMérieux as a sister company, under Institut Mérieux
2011
ABL opens Rockville, MD headquarters
2014
ABL acquires Platine Pharma in Lyon and built GCLP testing labs
2016
Creation of the first ABL entity in France through the acquisition of the Transgene production asset in Strasbourg*
* Expansion of ABL capabilities through the viral vector manufacturing plant, certified GMP in 1995.
2018
Creation of the second ABL entity in France through the acquisition of the Accinov innovative platform in Lyon
ABL is fully owned by Institut Mérieux.
OUR MISSION & VISION
OUR MISSION: By accelerating our Customer’s life-saving innovations, ABL is contributing to a long-term public health vision where Bio-Industry has a central role for a healthier world.
OUR VISION: Become a leading global biomanufacturing CDMO trusted to deliver innovation and excellence. We empower people. We foster an entrepreneurial culture. We commit to sustainability.
WHAT DO WE OFFER?
ABL
Your solution provider
Please accept marketing cookies to watch this video.
Developing and manufacturing viral vectors for over 25 years
Read more
We had our first facility GMP certified in 1995.
We produce a wide range of viral vectors: Vaccinia, MVA, Adeno, Measles, ORF, Arenavirus, AAV and others.
From the early clinical phases, we consider the cost to the patients.
Innovative treatments must be affordable to respond to unmet medical needs.
To help you bring sustainable solutions to the market, we do not hesitate to test emerging innovations and cutting-edge technologies.
Dedicated project management
Read more
An open and mutual collaboration with you and your team is key to meet your project objectives and overcome technical challenges.
For each project, we assign a dedicated Project Manager (PM) who will be your main point of contact throughout the collaboration.
The PM supervises each step of the process, from project kick off, technical meetings to daily management of the multidisciplinary teams working on your project.
To provide you with the best quality services, we ensure continuous training and improvement of our ways of working.
Effective quality control capabilities essential for your success
Read more
Within an international competitive environment, right first time and in due time is critical for a successful submission, approval and launching.
In close collaboration with your team we will design and execute a detailed and robust process and analytical development plan, phase appropriate, accordingly to your product specification and overall project milestones. You can rely on our extensive experience with dossier submission and interaction with major health authorities. We generate all the necessary data package to make your discussion with health authorities a success.
Flexibility within our contracts
Read more
Our contracts are based on milestones achievements.
We will facilitate tech transfer to another site if required. We acknowledge that you need flexibility to support a potential licensing out strategy.
Transparency, including on pricing revision indexation, is a key word at ABL Fast into Clinic: ABL is organized to implement a lean and seamless process to minimize the timing from RFP reception to delivery of first material you need, without compromising with the quality.
Customer centricity
Read more
You are at the center of our strategic decisions.
We offer you an hollistic approach, including solutions beyond the product manufacturing.
You can rely on our skilled and passionate teams to make your CMC journey easier and faster to market.
Talented teams to deliver the highest level of services
Read more
People are key assets within ABL, we consider that skills and experience of our collaborators are critical to bring value to your projects.
We foster diversity and creativity.
We encourage the continuous improvement through:
The versatility and adaptability of our manufacturing team to meet timelines without compromising quality.
Cross fertilization between our sites to implement the best practices and to organize seamless and efficient tech transfer.
Continuous training of our technicians and engineers through partnership with recognized universities having development and manufacturing fab-labs.
